The pharma giant didn't release the data -- it's saving it for a medical meeting -- but Pfizer did say the trial showed that the drug was better than placebo in multiple scales used to determine the severity of rheumatoid arthritis.
In the previous trial, 59.8% of patients reported 20% improvement of their symptoms, while the higher dose helped 65.7% of patients to report the same. The results were double the 26.7% of the patients taking placebo that improved their symptoms by 20%.
Tofacitinib should have little problem competing with the megablockbuster rheumatoid arthritis drugs -- Abbott Labs'
The biggest obstacle to tofacitinib's success isn't what's in front of it, but what's trailing behind. Rigel Pharmaceuticals
If the drugs work as well or better than tofacitinib, the head start Pfizer has might not amount to much. However, if they stumble in their respective phase 3 trials, Pfizer will have a major seller on its hands. Sales might not approach Lipitor's $12-billion scale, but billions -- with an "s" -- certainly isn't out of the question.
Pfizer isn't ready to submit a marketing application just yet. Tofacitinib still has four more trials to read out for rheumatoid arthritis, and multiple others in additional inflammatory diseases such as psoriasis and inflammatory bowel disease. Assuming the drug continues the clinical trial success, the results will be worth the wait.
Follow Pfizer as it tries to replace lost sales from Lipitor. Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on Pfizer.
Johnson & Johnson and Pfizer are Motley Fool Inside Value selections. Johnson & Johnson is a Motley Fool Income Investor pick. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Abbott Laboratories, and Johnson & Johnson. Motley Fool Alpha owns shares of Abbott Laboratories and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.